Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1128316 | 1.00 | KDM6B (0.44) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL156391 | 0.94 | — | — | |
| SCHEMBL10764532 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL7488654 | 0.90 | — | — | |
| SCHEMBL743846 | 0.90 | — | — | |
| SCHEMBL8995960 | 0.73 | ALDH1A1 (0.41) | KDM6BKDM5CEGLN1PHF8KDM2A | |
| SCHEMBL10619133 | 0.73 | — | — | |
| Acetic Acid SCHEMBL9621249 | 0.71 | FFAR3 (0.70) | FFAR3LCKFYNALDH1A1TSHR | |
| Acetic Acid SCHEMBL153379 | 0.71 | — | — | |
| SCHEMBL28818985 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060099256-A1 | Microspheres and related processes and pharmaceutical compositions | PRICE JAMES C | 2006-05-11 | — | — | US | claimed |
| EP-1526843-A1 | METHOD OF PREPARING SOLID DOSAGE FORMS COATED IN TWO LAYERS COMPRISING A WATER-INSOLUBLE POLYMER AND A WATER-SOLUBLE PORE FORMER | Pharmacia Corporation (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040137156-A1 | Coated solid dosage form and method for preparing same | LEE ERNEST J | 2004-07-15 | — | — | US | claimed |
| WO-2004050066-A1 | MICROSPHERES AND RELATED PROCESSES AND PHARMACEUTICAL COMPOSITIONS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| WO-2004010982-A1 | METHOD OF PREPARING SOLID DOSAGE FORMS COATED IN TWO LAYERS COMPRISING A WATER-INSOLUBLE POLYMER AND A WATER-SOLUBLE PORE FORMER | PHARMACIA CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| US-5458887-A | OF AN OSMOTIC CORE CONTAINING A DRUG AND A WATER SWELLABLE COMPONENT AND A WATER RESISTANT POLYMER COATING CONTAINING A COMPOUND WHICH DISSOLVES IN GASTROINTESTINAL FLUID | ANDRX PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | claimed |
| US-20210322408-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2021-10-21 | — | — | US | disclosed |
| US-20190314369-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2019-10-17 | — | — | US | disclosed |
| EP-2392326-B9 | Silibinin component for the treatment of hepatitis | MADAUS GMBH (DE) | 2018-09-05 | — | — | EP | disclosed |
| US-10064817-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-9919050-B2 | Compositions comprising azelastine | MEDA PHARMACEUTICALS INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2392326-B1 | Silibinin component for the treatment of hepatitis | MADAUS GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| WO-2017134524-A2 | SPHERICAL MICROCAPSULES WITH ENHANCED ORAL BIOAVAILABILITY | I2O Pharma Ltd. (IL) | 2017-08-10 | — | — | WO | disclosed |
| US-20010033866-A1 | Sustained release oral formulations | OGORKA JORG (DE) | 2001-10-25 | — | — | US | disclosed |
| EP-1121104-A2 | NEW SUSTAINED RELEASE ORAL FORMULATIONS | Novartis AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001022944-A1 | ORAL CONTROLLED RELEASE FORMULATIONS | NOVARTIS AG (CH) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000074661-A2 | SOLUBILITY ENHANCEMENT OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS AND METHODS OF USE | NOVEN PHARMACEUTICALS, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000019985-A2 | NEW SUSTAINED RELEASE ORAL FORMULATIONS | NOVARTIS AG (CH) | 2000-04-13 | — | — | WO | disclosed |
| US-5458887-A | OF AN OSMOTIC CORE CONTAINING A DRUG AND A WATER SWELLABLE COMPONENT AND A WATER RESISTANT POLYMER COATING CONTAINING A COMPOUND WHICH DISSOLVES IN GASTROINTESTINAL FLUID | ANDRX PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| US-5271946-A | Controlled release azelastine-containing pharmaceutical compositions | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1993-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322408-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | BTK, LCK, SYK | KDM6B 474/4885KDM5C 382/4885EGLN1 3993/4885 |
| US-10064817-B2 | Compositions comprising azelastine and methods of use thereof | TAS2R5, TAS2R31, TAS2R40 | KDM6B 581/4885KDM5C 429/4885EGLN1 1455/4885 |
| US-20190314369-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | BTK, LCK, SYK | KDM6B 474/4885KDM5C 382/4885EGLN1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.